Current and future therapies targeting the immune system in multiple sclerosis

Current Pharmaceutical Biotechnology

Volumn 15, Issue 3, 2014, Pages 276-296

  Loleit, Verena ^a   Biberacher, Viola ^a   Hemmer, Bernhard ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

Dimethyl fumarate; Fingolimod; Glatiramer acetate; Interferons; Multiple sclerosis; Natalizumab; Teriflunomide

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CENTRAL NERVOUS SYSTEM AGENTS; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GSK 2018682; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; ONO 4641; PEGINTERFERON BETA1A; PLACEBO; PONESIMOD; RALENOVA; RITUXIMAB; RPC 1063; SIPONIMOD; TERIFLUNOMIDE; UNCLASSIFIED DRUG; B7 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CERALIFIMOD; GAMMA INTERFERON; GSK2018682; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; OSTEOPONTIN; RPC1063; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CROTONIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; INTERFERON; MONOCLONAL ANTIBODY; TOLUIDINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANXIETY DISORDER; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE DISEASE; BRADYCARDIA; CARDIOTOXICITY; CHEST TIGHTNESS; CHILL; COUGHING; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HAIR LOSS; HEART PALPITATION; HERPES VIRUS INFECTION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LEUKOPENIA; LIPOATROPHY; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MULTIPLE SCLEROSIS; MYALGIA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RETINA MACULA EDEMA; REVIEW; RISK FACTOR; SCORING SYSTEM; SKIN DISEASE; SWELLING; ARTICLE; BLOOD BRAIN BARRIER; BORDERLINE HYPERTENSION; CYTOKINE RESPONSIVE ELEMENT; DISEASE ACTIVITY; DRUG MECHANISM; DRUG TARGETING; ENCEPHALITIS; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; IMMUNE SYSTEM; LIVER DYSFUNCTION; MACULAR EDEMA; MULTICENTER STUDY (TOPIC); PROTEIN EXPRESSION; RECURRENT DISEASE; THYROID DISEASE; VASOSPASM; VIRUS REPLICATION; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CROTONATES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; MITOXANTRONE; MULTIPLE SCLEROSIS; TOLUIDINES;

EID: 84907351542     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140617104332     Document Type: Review

References (245)

1. Sawcer, S.; Hellenthal, G.; Pirinen, M.; Spencer, C.C.; Patsopoulos, N.A.; Moutsianas, L.; Dilthey, A.; Su, Z.; Freeman, C.; Hunt, S.E.; Edkins, S.; Gray, E.; Booth, D.R.; Potter, S.C.; Goris, A.; Band, G.; Oturai, A.B.; Strange, A.; Saarela, J.; Bellenguez, C.; Fontaine, B.; Gillman, M.; Hemmer, B.; Gwilliam, R.; Zipp, F.; Jayakumar, A.; Martin, R.; Leslie, S.; Hawkins, S.; Giannoulatou, E.; D'alfonso, S.; Blackburn, H.; Martinelli Boneschi, F.; Liddle, J.; Harbo, H.F.; Perez, M.L.; Spurkland, A.; Waller, M.J.; Mycko, M.P.; Ricketts, M.; Comabella, M.; Hammond, N.; Kockum, I.; McCann, O.T.; Ban, M.; Whittaker, P.; Kemppinen, A.; Weston, P.; Hawkins, C.; Widaa, S.; Zajicek, J.; Dronov, S.; Robertson, N.; Bumpstead, S.J.; Barcellos, L.F.; Ravindrarajah, R.; Abraham, R.; Alfredsson, L.; Ardlie, K.; Aubin, C.; Baker, A.; Baker, K.; Baranzini, S.E.; Bergamaschi, L.; Bergamaschi, R.; Bernstein, A.; Berthele, A.; Boggild, M.; Bradfield, J.P.; Brassat, D.; Broadley, S.A.; Buck, D.; Butzkueven, H.; Capra, R.; Carroll, W.M.; Cavalla, P.; Celius, E.G.; Cepok, S.; Chiavacci, R.; Clerget-Darpoux, F.; Clysters, K.; Comi, G.; Cossburn, M.; Cournu-Rebeix, I.; Cox, M.B.; Cozen, W.; Cree, B.A.; Cross, A.H.; Cusi, D.; Daly, M.J.; Davis, E.; de Bakker, P. I.; Debouverie, M.; D'hooghe, M.B.; Dixon, K.; Dobosi, R.; Dubois, B.; Ellinghaus, D.; Elovaara, I.; Esposito, F.; Fontenille, C.; Foote, S.; Franke, A.; Galimberti, D.; Ghezzi, A.; Glessner, J.; Gomez, R.; Gout, O.; Graham, C.; Grant, S. F.; Guerini, F.R.; Hakonarson, H.; Hall, P.; Hamsten, A.; Hartung, H.P.; Heard, R.N.; Heath, S.; Hobart, J.; Hoshi, M.; Infante-Duarte, C.; Ingram, G.; Ingram, W.; Islam, T.; Jagodic, M.; Kabesch, M.; Kermode, A.G.; Kilpatrick, T.J.; Kim, C.; Klopp, N.; Koivisto, K.; Larsson, M.; Lathrop, M.; Lechner-Scott, J.S.; Leone, M.A.; Leppä, V.; Liljedahl, U.; Bomfim, I.L.; Lincoln, R.R.; Link, J.; Liu, J.; Lorentzen, A.R.; Lupoli, S.; Macciardi, F.; Mack, T.; Marriott, M.; Martinelli, V.; Mason, D.; McCauley, J.L.; Mentch, F.; Mero, I.L.; Mihalova, T.; Montalban, X.; Mottershead, J.; Myhr, K.M.; Naldi, P.; Ollier, W.; Page, A.; Palotie, A.; Pelletier, J.; Piccio, L.; Pickersgill, T.; Piehl, F.; Pobywajlo, S.; Quach, H.L.; Ramsay, P. P.; Reunanen, M.; Reynolds, R.; Rioux, J.D.; Rodegher, M.; Roesner, S.; Rubio, J.P.; Rückert, I.M.; Salvetti, M.; Salvi, E.; Santaniello, A.; Schaefer, C.A.; Schreiber, S.; Schulze, C.; Scott, R. J.; Sellebjerg, F.; Selmaj, K.W.; Sexton, D.; Shen, L.; Simms-Acuna, B.; Skidmore, S.; Sleiman, P.M.; Smestad, C.; Sørensen, P.S.; Søndergaard, H.B.; Stankovich, J.; Strange, R.C.; Sulonen, A.M.; Sundqvist, E.; Syvänen, A.C.; Taddeo, F.; Taylor, B.; Blackwell, J.M.; Tienari, P.; Bramon, E.; Tourbah, A.; Brown, M. A.; Tronczynska, E.; Casas, J.P.; Tubridy, N.; Corvin, A.; Vickery, J.; Jankowski, J.; Villoslada, P.; Markus, H.S.; Wang, K.; Mathew, C.G.; Wason, J.; Palmer, C.N.; Wichmann, H.E.; Plomin, R.; Willoughby, E.; Rautanen, A.; Winkelmann, J.; Wittig, M.; Trembath, R.C.; Yaouanq, J.; Viswanathan, A.C.; Zhang, H.; Wood, N.W.; Zuvich, R.; Deloukas, P.; Langford, C.; Duncanson, A.; Oksenberg, J.R.; Pericak-Vance, M.A.; Haines, J.L.; Olsson, T.; Hillert, J.; Ivinson, A.J.; De Jager, P.L.; Peltonen, L.; Stewart, G.J.; Hafler, D.A.; Hauser, S.L.; McVean, G.; Donnelly, P.; Compston, A.; Consortium, I.M.S.G.; 2, W.T.C.C.C. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476(7359), 214-219.
2. Beecham, A.H.; Patsopoulos, N.A.; Xifara, D.K.; Davis, M.F.; Kemppinen, A.; Cotsapas, C.; Shah, T.S.; Spencer, C.; Booth, D.; Goris, A.; Oturai, A.; Saarela, J.; Fontaine, B.; Hemmer, B.; Martin, C.; Zipp, F.; D'Alfonso, S.; Martinelli-Boneschi, F.; Taylor, B.; Harbo, H.F.; Kockum, I.; Hillert, J.; Olsson, T.; Ban, M.; Oksenberg, J.R.; Hintzen, R.; Barcellos, L.F.; Agliardi, C.; Alfredsson, L.; Alizadeh, M.; Anderson, C.; Andrews, R.; Søndergaard, H.B.; Baker, A.; Band, G.; Baranzini, S.E.; Barizzone, N.; Barrett, J.; Bellenguez, C.; Bergamaschi, L.; Bernardinelli, L.; Berthele, A.; Biberacher, V.; Binder, T.M.; Blackburn, H.; Bomfim, I.L.; Brambilla, P.; Broadley, S.; Brochet, B.; Brundin, L.; Buck, D.; Butzkueven, H.; Caillier, S.J.; Camu, W.; Carpentier, W.; Cavalla, P.; Celius, E.G.; Coman, I.; Comi, G.; Corrado, L.; Cosemans, L.; Cournu-Rebeix, I.; Cree, B. A.; Cusi, D.; Damotte, V.; Defer, G.; Delgado, S.R.; Deloukas, P.; di Sapio, A.; Dilthey, A.T.; Donnelly, P.; Dubois, B.; Duddy, M.; Edkins, S.; Elovaara, I.; Esposito, F.; Evangelou, N.; Fiddes, B.; Field, J.; Franke, A.; Freeman, C.; Frohlich, I.Y.; Galimberti, D.; Gieger, C.; Gourraud, P.A.; Graetz, C.; Graham, A.; Grummel, V.; Guaschino, C.; Hadjixenofontos, A.; Hakonarson, H.; Halfpenny, C.; Hall, G.; Hall, P.; Hamsten, A.; Harley, J.; Harrower, T.; Hawkins, C.; Hellenthal, G.; Hillier, C.; Hobart, J.; Hoshi, M.; Hunt, S.E.; Jagodic, M.; Jelčić, I.; Jochim, A.; Kendall, B.; Kermode, A.; Kilpatrick, T.; Koivisto, K.; Konidari, I.; Korn, T.; Kronsbein, H.; Langford, C.; Larsson, M.; Lathrop, M.; Lebrun-Frenay, C.; Lechner-Scott, J.; Lee, M.H.; Leone, M.A.; Leppä, V.; Liberatore, G.; Lie, B.A.; Lill, C.M.; Lindén, M.; Link, J.; Luessi, F.; Lycke, J.; Macciardi, F.; Männistö, S.; Manrique, C.P.; Martin, R.; Martinelli, V.; Mason, D.; Mazibrada, G.; McCabe, C.; Mero, I.L.; Mescheriakova, J.; Moutsianas, L.; Myhr, K.M.; Nagels, G.; Nicholas, R.; Nilsson, P.; Piehl, F.; Pirinen, M.; Price, S.E.; Quach, H.; Reunanen, M.; Robberecht, W.; Robertson, N.P.; Rodegher, M.; Rog, D.; Salvetti, M.; Schnetz-Boutaud, N.C.; Sellebjerg, F.; Selter, R.C.; Schaefer, C.; Shaunak, S.; Shen, L.; Shields, S.; Siffrin, V.; Slee, M.; Sorensen, P.S.; Sorosina, M.; Sospedra, M.; Spurkland, A.; Strange, A.; Sundqvist, E.; Thijs, V.; Thorpe, J.; Ticca, A.; Tienari, P.; van Duijn, C.; Visser, E.M.; Vucic, S.; Westerlind, H.; Wiley, J.S.; Wilkins, A.; Wilson, J.F.; Winkelmann, J.; Zajicek, J.; Zindler, E.; Haines, J.L.; Pericak-Vance, M.A.; Ivinson, A.J.; Stewart, G.; Hafler, D.; Hauser, S.L.; Compston, A.; McVean, G.; De Jager, P.; Sawcer, S.J.; McCauley, J.L.; (IMSGC), I. M. S. G. C.; (WTCCC2), W. T. C. C. C.; (IIBDGC), I. I. G. C. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet., 2013, 45(11), 1353-1360.
3. Ascherio, A.; Munger, K.L., Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol., 2007, 61(4), 288-299.
4. Ascherio, A.; Munger, K.L., Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann. Neurol., 2007, 61(6), 504-513.
5. Hemmer, B.; Archelos, J.J.; Hartung, H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci., 2002, 3(4), 291-301.
6. Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol., 2005, 23, 683-747.
7. Korn, T.; Bettelli, E.; Oukka, M.; Kuchroo, V.K. IL-17 and Th17 Cells. Annu. Rev. Immunol., 2009, 27, 485-517.
8. Antel, J.; Bar-Or, A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol., 2006, 180(1-2), 3-8.
9. Cross, A.H.; Stark, J.L. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol. Res., 2005, 32(1-3), 85-97.
10. Hemmer, B.; Nessler, S.; Zhou, D.; Kieseier, B.; Hartung, H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol., 2006, 2(4), 201-211.
11. Frohman, E.M.; Racke, M.K.; Raine, C.S. Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med., 2006, 354(9), 942-955.
12. Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2008, 372(9648), 1502-1517.
13. Barkhof, F.; Simon, J.H.; Fazekas, F.; Rovaris, M.; Kappos, L.; de Stefano, N.; Polman, C.H.; Petkau, J.; Radue, E.W.; Sormani, M. P.; Li, D.K.; O'Connor, P.; Montalban, X.; Miller, D.H.; Filippi, M. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat. Rev. Neurol., 2012, 8(1), 13-21.
14. Isaacs, A.; Lindenmann, J. Virus interference. I. The interferon. Proc. R Soc. Lond. B Biol. Sci., 1957, 147(927), 258-267.
15. Jacobs, L.; O'Malley, J.; Freeman, A.; Ekes, R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science, 1981, 214(4524), 1026-1028.
16. Flenniken, A.M.; Galabru, J.; Rutherford, M.N.; Hovanessian, A.G.; Williams, B.R. Expression of interferon-induced genes in different tissues of mice. J. Virol., 1988, 62(9), 3077-3083.
17. Weinstock-Guttman, B.; Ransohoff, R.M.; Kinkel, R.P.; Rudick, R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol., 1995, 37(1), 7-15.
18. Liu, Z.; Pelfrey, C.M.; Cotleur, A.; Lee, J.C.; Rudick, R.A. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J. Neuroimmunol., 2001, 112(1-2), 153-62.
19. Kozovska, M.E.; Hong, J.; Zang, Y.C.; Li, S.; Rivera, V.M.; Killian, J.M.; Zhang, J.Z. Interferon beta induces T-helper 2 immune deviation in MS. Neurology, 1999, 53(8), 1692-1697.
20. Ozenci, V.; Kouwenhoven, M.; Huang, Y.M.; Xiao, B.; Kivisakk, P.; Fredrikson, S.; Link, H. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scan. J. Immunol., 1999, 49(5), 554-561.
21. Guo, B.; Chang, E.Y.; Cheng, G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest., 2008, 118(5), 1680-1690.
22. Zhang, L.; Yuan, S.; Cheng, G.; Guo, B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One, 2011, 6(12), e28432.
23. Ramgolam, V.S.; Sha, Y.; Jin, J.; Zhang, X.; Markovic-Plese, S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol., 2009, 183(8), 5418-5427.
24. Shinohara, M.L.; Kim, J.H.; Garcia, V.A.; Cantor, H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: Role of intracellular osteopontin. Immunity, 2008, 29(1), 68-78.
25. Chen, M.; Chen, G.; Nie, H.; Zhang, X.; Niu, X.; Zang, Y.C.; Skinner, S.M.; Zhang, J.Z.; Killian, J.M.; Hong, J. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur. J. Immunol., 2009, 39(9), 2525-2536.
26. Mirandola, S.R.; Hallal, D.E.; Farias, A.S.; Oliveira, E.C.; Brandao, C.O.; Ruocco, H.H.; Damasceno, B.P.; Santos, L.M. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int. Immunopharmacol., 2009, 9(7-8), 824-830.
27. de Andres, C.; Aristimuno, C.; de Las Heras, V.; Martinez-Gines, M.L.; Bartolome, M.; Arroyo, R.; Navarro, J.; Gimenez-Roldan, S.; Fernandez-Cruz, E.; Sanchez-Ramon, S. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol., 2007, 182(1-2), 204-211.
28. Korporal, M.; Haas, J.; Balint, B.; Fritzsching, B.; Schwarz, A.; Moeller, S.; Fritz, B.; Suri-Payer, E.; Wildemann, B. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch. Neurol., 2008, 65(11), 1434-1439.
29. Chen, M.; Chen, G.; Deng, S.; Liu, X.; Hutton, G.J.; Hong, J. IFNbeta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J. Neuroimmunol., 2012, 242(1-2), 39-46.
30. Saraste, M.; Irjala, H.; Airas, L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci., 2007, 28(3), 121-126.
31. Vandenbark, A.A.; Huan, J.; Agotsch, M.; La Tocha, D.; Goelz, S.; Offner, H.; Lanker, S.; Bourdette, D. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol., 2009, 215(1-2), 125-128.
32. Martinez-Rodriguez, J.E.; Lopez-Botet, M.; Munteis, E.; Rio, J.; Roquer, J.; Montalban, X.; Comabella, M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol., 2011, 141(3), 348-356.
33. Ramgolam, V.S.; Sha, Y.; Marcus, K.L.; Choudhary, N.; Troiani, L.; Chopra, M.; Markovic-Plese, S. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J. Immunol., 2011, 186(7), 4518-4526.
34. Kraus, J.; Voigt, K.; Schuller, A.M.; Scholz, M.; Kim, K.S.; Schilling, M.; Schabitz, W.R.; Oschmann, P.; Engelhardt, B. Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro. Mult. Scler., 2008, 14(6), 843-852.
35. Kieseier, B.C. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs, 2011, 25(6), 491-502.
36. Cepok, S.; Schreiber, H.; Hoffmann, S.; Zhou, D.; Neuhaus, O.; von Geldern, G.; Hochgesand, S.; Nessler, S.; Rothhammer, V.; Lang, M.; Hartung, H.P.; Hemmer, B. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch. Neurol., 2009, 66(10), 1216-1223.
37. Paty, D.W.; Li, D.K. Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 1993, 43(4), 662-667.
38. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology, 1993, 43(4), 655-661.
39. Runkel, L.; Meier, W.; Pepinsky, R.B.; Karpusas, M.; Whitty, A.; Kimball, K.; Brickelmaier, M.; Muldowney, C.; Jones, W.; Goelz, S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res., 1998, 15(4), 641-649.
40. Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.; Simon, J.H.; Alam, J.J.; Bartoszak, D.M.; Bourdette, D.N.; Braiman, J.; Brownscheidle, C.M.; Coats, M.E.; Cohan, S.L.; Dougherty, D.S.; Kinkel, R.P.; Mass, M.K.; Munschauer, F.E., 3rd; Priore, R.L.; Pullicino, P.M.; Scherokman, B.J.; Whitham, R.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol., 1996, 39(3), 285-294.
41. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 1998, 352(9139), 1498-1504.
42. Jacobs, L.D.; Beck, R.W.; Simon, J.H.; Kinkel, R.P.; Brownscheidle, C.M.; Murray, T.J.; Simonian, N.A.; Slasor, P.J.; Sandrock, A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med., 2000, 343(13), 898-904.
43. Kappos, L.; Polman, C.H.; Freedman, M.S.; Edan, G.; Hartung, H. P.; Miller, D.H.; Montalban, X.; Barkhof, F.; Bauer, L.; Jakobs, P.; Pohl, C.; Sandbrink, R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2006, 67(7), 1242-1249.
44. Comi, G.; De Stefano, N.; Freedman, M.S.; Barkhof, F.; Polman, C.H.; Uitdehaag, B.M.; Casset-Semanaz, F.; Hennessy, B.; Moraga, M.S.; Rocak, S.; Stubinski, B.; Kappos, L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol., 2012, 11(1), 33-41.
45. Kappos, L.; Freedman, M.S.; Polman, C.H.; Edan, G.; Hartung, H. P.; Miller, D.H.; Montalban, X.; Barkhof, F.; Radu, E.W.; Metzig, C.; Bauer, L.; Lanius, V.; Sandbrink, R.; Pohl, C. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol., 2009, 8(11), 987-997.
46. Edan, G.; Kappos, L.; Montalban, X.; Polman, C.; Freedman, M.; Hartung, H.-P.; Miller, D.; Barkhof, F.; Herrmann, J.; Lanius, V.; Stemper, B.; Pohl, C.; Sandbrink, R.; Pleimes, D. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year Observational extension of the phase 3 BENEFIT Trial. In ECTRIMS, Amsterdam (Netherlands), 2011.
47. Kinkel, R.P.; Dontchev, M.; Kollman, C.; Skaramagas, T.T.; O'Connor, P.W.; Simon, J.H. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch. Neurol., 2012, 69(2), 183-190.
48. Ebers, G.C.; Traboulsee, A.; Li, D.; Langdon, D.; Reder, A.T.; Goodin, D.S.; Bogumil, T.; Beckmann, K.; Wolf, C.; Konieczny, A. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J. Neurol. Neurosurg. Psychiat., 2010, 81(8), 907-912.
49. Goodin, D.S.; Reder, A.T.; Ebers, G.C.; Cutter, G.; Kremenchutzky, M.; Oger, J.; Langdon, D.; Rametta, M.; Beckmann, K.; DeSimone, T.M.; Knappertz, V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology, 2012, 78(17), 1315-1322.
50. Shirani, A.; Zhao, Y.; Karim, M.E.; Evans, C.; Kingwell, E.; van der Kop, M.L.; Oger, J.; Gustafson, P.; Petkau, J.; Tremlett, H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA, 2012, 308(3), 247-256.
51. Trojano, M.; Pellegrini, F.; Fuiani, A.; Paolicelli, D.; Zipoli, V.; Zimatore, G.B.; Di Monte, E.; Portaccio, E.; Lepore, V.; Livrea, P.; Amato, M.P. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol., 2007, 61(4), 300-306.
52. Goodin, D.S.; Reder, A.T.; Cutter, G. Treatment with interferon beta for multiple sclerosis. JAMA, 2012, 308(16), 1627; author reply 1627-1628.
53. Renoux, C.; Suissa, S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol 2008, 64(1), 109-10; author reply 110.
54. Panitch, H.; Miller, A.; Paty, D.; Weinshenker, B. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology, 2004, 63(10), 1788-1795.
55. Kappos, L.; Weinshenker, B.; Pozzilli, C.; Thompson, A.J.; Dahlke, F.; Beckmann, K.; Polman, C.; McFarland, H. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology, 2004, 63(10), 1779-1787.
56. Mantia, L.L.; Vacchi, L.; Rovaris, M.; Di Pietrantonj, C.; Ebers, G.; Fredrikson, S.; Filippini, G. Interferon beta for secondary progressive multiple sclerosis: a systematic review. J. Neurol. Neurosurg. Psychiat., 2013, 84(4), 420-426.
57. Kappos, L.; Polman, C.; Pozzilli, C.; Thompson, A.; Beckmann, K.; Dahlke, F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology, 2001, 57(11), 1969-1675.
58. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology, 2001, 56(11), 1496-1504.
59. Li, D.K.; Zhao, G.J.; Paty, D.W. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology, 2001, 56(11), 1505-1513.
60. Rojas, J.I.; Romano, M.; Ciapponi, A.; Patrucco, L.; Cristiano, E. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst. Rev., 2009, (1), CD006643.
61. Leary, S.M.; Miller, D.H.; Stevenson, V.L.; Brex, P.A.; Chard, D.T.; Thompson, A.J. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology, 2003, 60(1), 44-51.
62. Tur, C.; Montalban, X.; Tintore, M.; Nos, C.; Rio, J.; Aymerich, F. X.; Brieva, L.; Tellez, N.; Perkal, H.; Comabella, M.; Galan, I.; Calle, D.; Sastre-Garriga, J.; Rovira, A. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch. Neurol., 2011, 68(11), 1421-1427.
63. Kim, S.H.; Kim, W.; Li, X.F.; Jung, I.J.; Kim, H.J. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult. Scler., 2012, 18(10), 1480-1483.
64. Bonaci-Nikolic, B.; Jeremic, I.; Andrejevic, S.; Sefik-Bukilica, M.; Stojsavljevic, N.; Drulovic, J. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus, 2009, 18(1), 78-80.
65. Sladkova, V.; Mares, J.; Lubenova, B.; Hlustik, P.; Kanovsky, P. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro. Endocrinol. Lett., 2011, 32(1), 4-6.
66. Durelli, L.; Ferrero, B.; Oggero, A.; Verdun, E.; Bongioanni, M.R.; Gentile, E.; Isoardo, G.L.; Ricci, A.; Rota, E.; Bergamasco, B.; Durazzo, M.; Saracco, G.; Biava, M.A.; Brossa, P.C.; Giorda, L.; Pagni, R.; Aimo, G. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J. Neurologic. Sci., 1999, 162(1), 74-83.
67. Schwid, S.R.; Goodman, A.D.; Mattson, D.H. AUtoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Archiv. Neurol., 1997, 54(9), 1169-1170.
68. Rio, J.; Nos, C.; Bonaventura, I.; Arroyo, R.; Genis, D.; Sureda, B.; Ara, J.R.; Brieva, L.; Martin, J.; Saiz, A.; Sanchez Lopez, F.; Prieto, J.M.; Roquer, J.; Dorado, J.F.; Montalban, X. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology, 2004, 63(3), 525-528.
69. Walther, E.U.; Hohlfeld, R. Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology, 1999, 53(8), 1622-1627.
70. Beer, K.; Muller, M.; Hew-Winzeler, A.M.; Bont, A.; Maire, P.; You, X.; Foulds, P.; Marlind, J.; Curtius, D. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol., 2011, 11, 144.
71. Monzani, F.; Caraccio, N.; Meucci, G.; Lombardo, F.; Moscato, G.; Casolaro, A.; Ferdeghini, M.; Murri, L.; Ferrannini, E. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Europ. J. Endocrinol., 1999, 141(4), 325-331.
72. Tremlett, H.L.; Yoshida, E.M.; Oger, J. Liver injury associated with the beta-interferons for MS: A comparison between the three products. Neurology, 2004, 62(4), 628-631.
73. Zephir, H.; De Seze, J.; Stojkovic, T.; Delisse, B.; Ferriby, D.; Cabaret, M.; Vermersch, P. Multiple sclerosis and depression: influence of interferon beta therapy. Mult. Scler., 2003, 9(3), 284-8.
74. Panitch, H.; Goodin, D.S.; Francis, G.; Chang, P.; Coyle, P.K.; O'Connor, P.; Monaghan, E.; Li, D.; Weinshenker, B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 2002, 59(10), 1496-1506.
75. Schwid, S.R.; Panitch, H.S. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessorblinded comparison of low-dose weekly versus high-dose, highfrequency interferon beta-1a for relapsing multiple sclerosis. Clin. Ther., 2007, 29(9), 2031-2048.
76. Durelli, L.; Verdun, E.; Barbero, P.; Bergui, M.; Versino, E.; Ghezzi, A.; Montanari, E.; Zaffaroni, M. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 2002, 359(9316), 1453-1460.
77. Barbero, P.; Bergui, M.; Versino, E.; Ricci, A.; Zhong, J.J.; Ferrero, B.; Clerico, M.; Pipieri, A.; Verdun, E.; Giordano, L.; Durelli, L. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult. Scler., 2006, 12(1), 72-76.
78. Rio, J.; Nos, C.; Tintore, M.; Tellez, N.; Galan, I.; Pelayo, R.; Comabella, M.; Montalban, X. Defining the response to interferonbeta in relapsing-remitting multiple sclerosis patients. Ann. Neurol., 2006, 59(2), 344-352.
79. Comabella, M.; Lunemann, J.D.; Rio, J.; Sanchez, A.; Lopez, C.; Julia, E.; Fernandez, M.; Nonell, L.; Camina-Tato, M.; Deisenhammer, F.; Caballero, E.; Tortola, M.T.; Prinz, M.; Montalban, X.; Martin, R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain, 2009, 132(Pt 12), 3353-3365.
80. Axtell, R.C.; de Jong, B.A.; Boniface, K.; van der Voort, L.F.; Bhat, R.; De Sarno, P.; Naves, R.; Han, M.; Zhong, F.; Castellanos, J.G.; Mair, R.; Christakos, A.; Kolkowitz, I.; Katz, L.; Killestein, J.; Polman, C.H.; de Waal Malefyt, R.; Steinman, L.; Raman, C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med., 2010, 16(4), 406-412.
81. Bushnell, S.E.; Zhao, Z.; Stebbins, C.C.; Cadavid, D.; Buko, A.M.; Whalley, E.T.; Davis, J.A.; Versage, E.M.; Richert, J.R.; Axtell, R.C.; Steinman, L.; Medori, R. Serum IL-17F does not predict poor response to IM IFNÎ2-1a in relapsing-remitting MS. Neurology, 2012, 79(6), 531-537.
82. Hesse, D.; Sorensen, P.S. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur. J. Neurol., 2007, 14(8), 850-859.
83. Bertolotto, A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr. Opin. Neurol., 2004, 17(3), 241-246.
84. Ross, C.; Clemmesen, K.M.; Svenson, M.; Sorensen, P.S.; Koch-Henriksen, N.; Skovgaard, G.L.; Bendtzen, K. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol., 2000, 48(5), 706-712.
85. Hemmer, B.; Stuve, O.; Kieseier, B.; Schellekens, H.; Hartung, H.P. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol., 2005, 4(7), 403-412.
86. Grossberg, S.E.; Oger, J.; Grossberg, L.D.; Gehchan, A.; Klein, J.P. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J. Interferon Cytokine Res., 2011.
87. Bertolotto, A.; Sala, A.; Malucchi, S.; Marnetto, F.; Caldano, M.; Di Sapio, A.; Capobianco, M.; Gilli, F. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiat., 2004, 75(9), 1294-1299.
88. Sorensen, P.S.; Koch-Henriksen, N.; Ross, C.; Clemmesen, K.M.; Bendtzen, K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology, 2005, 65(1), 33-39.
89. Bertolotto, A.; Malucchi, S.; Sala, A.; Orefice, G.; Carrieri, P.B.; Capobianco, M.; Milano, E.; Melis, F.; Giordana, M.T. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiat., 2002, 73(2), 148-153.
90. Sominanda, A.; Rot, U.; Suoniemi, M.; Deisenhammer, F.; Hillert, J.; Fogdell-Hahn, A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult. Scler., 2007, 13(2), 208-214.
91. Paolicelli, D.; D'Onghia, M.; Pellegrini, F.; Direnzo, V.; Iaffaldano, P.; Lavolpe, V.; Trojano, M. The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing study. J. Neurol., 2013, 260(6), 1562-1568.
92. Sorensen, P.S.; Ross, C.; Clemmesen, K.M.; Bendtzen, K.; Frederiksen, J.L.; Jensen, K.; Kristensen, O.; Petersen, T.; Rasmussen, S.; Ravnborg, M.; Stenager, E.; Koch-Henriksen, N. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet, 2003, 362(9391), 1184-1191.
93. Goodin, D.S.; Hartung, H.P.; O'Connor, P.; Filippi, M.; Arnason, B.; Comi, G.; Cook, S.; Jeffery, D.; Kappos, L.; Bogumil, T.; Knappertz, V.; Sandbrink, R.; Beckmann, K.; White, R.; Petkau, J.; Pohl, C. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult. Scler., 2012, 18(2), 181-195.
94. Hartung, H.P.; Freedman, M.S.; Polman, C.H.; Edan, G.; Kappos, L.; Miller, D.H.; Montalban, X.; Barkhof, F.; Petkau, J.; White, R.; Sahajpal, V.; Knappertz, V.; Beckmann, K.; Lanius, V.; Sandbrink, R.; Pohl, C. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology, 2011, 77(9), 835-843.
95. Polman, C.H.; Bertolotto, A.; Deisenhammer, F.; Giovannoni, G.; Hartung, H.P.; Hemmer, B.; Killestein, J.; McFarland, H.F.; Oger, J.; Pachner, A.R.; Petkau, J.; Reder, A.T.; Reingold, S.C.; Schellekens, H.; Sorensen, P.S. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol., 2010, 9(7), 740-750.
96. Bertolotto, A.; Gilli, F.; Sala, A.; Audano, L.; Castello, A.; Magliola, U.; Melis, F.; Giordana, M.T. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods, 2001, 256(1-2), 141-152.
97. Bermel, R.A.; You, X.; Foulds, P.; Hyde, R.; Simon, J.H.; Fisher, E.; Rudick, R.A. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann. Neurol., 2013, 73(1), 95-103.
98. Reuss, R. PEGylated interferon beta-1a in the treatment of multiple sclerosis-an update. Biologics, 2013, 7, 131-138.
99. Calabresi, P.; Kieseier, B.; Arnold, D.; Balcer, L.; Boyko, A.; Pelletier, J.; Liu, S.; Zhu, Y.; You, X.; Seddighzadeh, A.; Sperling, B.; Hung, S.; Deykin, A. Peginterferon beta-1a provides improvements in clinical and radiological disease activity in relapsing-remitting multiple sclerosis: Year 1 findings from the phase 3 ADVANCE study. In Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 2013.
100. Deykin, A.; Douglas, A.; Hung, S.; Sheikh, S.; Seddighzadeh, A.; Zhu, Y.; Liu, S.; Kieseier, B. Interim analysis of 2-year clinical efficacy and safety of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: Data from the pivotal phase 3 ADVANCE Study. In American Academy of Neurology, Annual Meeting, Philadelphia, United States, 2014.
101. Douglas, A.; Kieseier, B.; Sheikh, S.; Deykin, A.; Zhu, Y.; You, X.; Sperling, B.; Hung, S. Peginterferon beta-1a significantly increases the proportion of patients with freedom from measured disease activity in relapsing-remitting multiple sclerosis: Findings from the ADVANCE Study. In American Academy of Neurology, Annual Meeting, Philadelphia, United States, 2014.
102. Kieseier, B.; Calabresi, P.; Liu, S.; Zhu, Y.; You, X.; Sperling, B.; Sheikh, S.; Hung, S.; Deykin, A. Effect of peginterferon beta-1a on disability progression in patients with relapsing remitting multiple sclerosis: year 1 data from the pivotal phase 3 ADVANCE study. In Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 2013.
103. Arnon, R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: Personal reflections. Immunol. Lett., 1996, 50(1-2), 1-15.
104. Teitelbaum, D.; Meshorer, A.; Hirshfeld, T.; Arnon, R.; Sela, M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol., 1971, 1(4), 242-248.
105. Abramsky, O.; Teitelbaum, D.; Arnon, R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J. Neurol. Sci., 1977, 31(3), 433-438.
106. Bornstein, M.B.; Miller, A.I.; Teitelbaum, D.; Arnon, R.; Sela, M. Multiple sclerosis: trial of a synthetic polypeptide. Ann. Neurol., 1982, 11(3), 317-319.
107. Duda, P.W.; Krieger, J.I.; Schmied, M.C.; Balentine, C.; Hafler, D.A. Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol., 2000, 165(12), 7300-7307.
108. Miller, A.; Shapiro, S.; Gershtein, R.; Kinarty, A.; Rawashdeh, H.; Honigman, S.; Lahat, N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol., 1998, 92(1-2), 113-121.
109. Chen, M.; Gran, B.; Costello, K.; Johnson, K.; Martin, R.; Dhib-Jalbut, S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler., 2001, 7(4), 209-219.
110. Neuhaus, O.; Farina, C.; Yassouridis, A.; Wiendl, H.; Then Bergh, F.; Dose, T.; Wekerle, H.; Hohlfeld, R. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7452-7.
111. Qin, Y.; Zhang, D.Q.; Prat, A.; Pouly, S.; Antel, J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol., 2000, 108(1-2), 201-206.
112. Duda, P.W.; Schmied, M.C.; Cook, S.L.; Krieger, J.I.; Hafler, D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest., 2000, 105(7), 967-976.
113. Aharoni, R.; Teitelbaum, D.; Sela, M.; Arnon, R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA, 1997, 94(20), 10821-10826.
114. Teitelbaum, D.; Milo, R.; Arnon, R.; Sela, M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci. USA, 1992, 89(1), 137-141.
115. Hong, J.; Li, N.; Zhang, X.; Zheng, B.; Zhang, J.Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. USA, 2005, 102 (18), 6449-6454.
116. Haas, J.; Korporal, M.; Balint, B.; Fritzsching, B.; Schwarz, A.; Wildemann, B. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+) CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol., 2009, 216(1-2), 113-117.
117. Izikson, L.; Klein, R.S.; Luster, A.D.; Weiner, H.L. Targeting monocyte recruitment in CNS autoimmune disease. Clin. Immunol., 2002, 103(2), 125-31.
118. Weber, M.S.; Starck, M.; Wagenpfeil, S.; Meinl, E.; Hohlfeld, R.; Farina, C. Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain, 2004, 127(Pt 6), 1370-1378.
119. Kim, H.J.; Ifergan, I.; Antel, J.P.; Seguin, R.; Duddy, M.; Lapierre, Y.; Jalili, F.; Bar-Or, A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol., 2004, 172(11), 7144-7153.
120. Li, Q.; Milo, R.; Panitch, H.; Swoveland, P.; Bever, C.T. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur J Pharmacol 1998, 342 (2-3), 303-310.
121. Vieira, P. L.; Heystek, H. C.; Wormmeester, J.; Wierenga, E. A.; Kapsenberg, M. L., Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol., 2003, 170(9), 4483-4488.
122. Weber, M.S.; Prod'homme, T.; Youssef, S.; Dunn, S.E.; Rundle, C.D.; Lee, L.; Patarroyo, J.C.; Stuve, O.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med., 2007, 13(8), 935-943.
123. Teitelbaum, D.; Brenner, T.; Abramsky, O.; Aharoni, R.; Sela, M.; Arnon, R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult. Scler., 2003, 9(6), 592-599.
124. Sellebjerg, F.; Hedegaard, C.J.; Krakauer, M.; Hesse, D.; Lund, H.; Nielsen, C.H.; Sondergaard, H.B.; Sorensen, P.S. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Mult. Scler., 2012, 18(3), 305-313.
125. Blanchette, F. Clinical significance of glatiramer acetate antibodies. Mult. Scler., 2007, 13(1 suppl), 28-35.
126. Bomprezzi, R.; Schafer, R.; Reese, V.; Misra, A.; Vollmer, T.L.; Kala, M. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. Scand. J. Immunol., 2011, 74(3), 219-226.
127. Ure, D.R.; Rodriguez, M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J., 2002, 16(10), 1260-1262.
128. Brenner, T.; Arnon, R.; Sela, M.; Abramsky, O.; Meiner, Z.; Riven-Kreitman, R.; Tarcik, N.; Teitelbaum, D. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J. Neuroimmunol., 2001, 115(1-2), 152-160.
129. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995, 45(7), 1268-1276.
130. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B.; Vollmer, T.; Weiner, L.P.; Wolinsky, J.S. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1998, 50(3), 701-708.
131. Comi, G.; Filippi, M.; Wolinsky, J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol., 2001, 49(3), 290-297.
132. Khan, O.; Rieckmann, P.; Boyko, A.; Selmaj, K.; Zivadinov, R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann. Neurol., 2013, 73(6), 705-713.
133. Comi, G.; Cohen, J.A.; Arnold, D.L.; Wynn, D.; Filippi, M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann. Neurol., 2011, 69(1), 75-82.
134. Comi, G.; Martinelli, V.; Rodegher, M.; Moiola, L.; Bajenaru, O.; Carra, A.; Elovaara, I.; Fazekas, F.; Hartung, H.P.; Hillert, J.; King, J.; Komoly, S.; Lubetzki, C.; Montalban, X.; Myhr, K.M.; Ravnborg, M.; Rieckmann, P.; Wynn, D.; Young, C.; Filippi, M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet, 2009, 374(9700), 1503-1511.
135. Miller, A.; Spada, V.; Beerkircher, D.; Kreitman, R.R. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler., 2008, 14(4), 494-499.
136. Ford, C.; Goodman, A.D.; Johnson, K.; Kachuck, N.; Lindsey, J. W.; Lisak, R.; Luzzio, C.; Myers, L.; Panitch, H.; Preiningerova, J.; Pruitt, A.; Rose, J.; Rus, H.; Wolinsky, J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler., 2010, 16(3), 342-350.
137. Wolinsky, J.S.; Narayana, P.A.; O'Connor, P.; Coyle, P.K.; Ford, C.; Johnson, K.; Miller, A.; Pardo, L.; Kadosh, S.; Ladkani, D. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol., 2007, 61(1), 14-24.
138. Edgar, C.M.; Brunet, D.G.; Fenton, P.; McBride, E.V.; Green, P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can. J. Neurol. Sci., 2004, 31(1), 58-63.
139. Farina, C.; Weber, M.S.; Meinl, E.; Wekerle, H.; Hohlfeld, R. Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action. Lancet Neurol., 2005, 4(9), 567-575.
140. Romeo, M.; Martinelli-Boneschi, F.; Rodegher, M.; Esposito, F.; Martinelli, V.; Comi, G. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Eur. J. Neurol., 2013, 20(7), 1060-1067.
141. Mikol, D.D.; Barkhof, F.; Chang, P.; Coyle, P.K.; Jeffery, D.R.; Schwid, S.R.; Stubinski, B.; Uitdehaag, B. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol., 2008, 7(10), 903-914.
142. O'Connor, P.; Filippi, M.; Arnason, B.; Comi, G.; Cook, S.; Goodin, D.; Hartung, H.P.; Jeffery, D.; Kappos, L.; Boateng, F.; Filippov, V.; Groth, M.; Knappertz, V.; Kraus, C.; Sandbrink, R.; Pohl, C.; Bogumil, T. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol., 2009, 8(10), 889-897.
143. Lublin, F.D.; Cofield, S.S.; Cutter, G.R.; Conwit, R.; Narayana, P. A.; Nelson, F.; Salter, A.R.; Gustafson, T.; Wolinsky, J.S. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann. Neurol., 2013, 73(3), 327-340.
144. Yednock, T.A.; Cannon, C.; Fritz, L.C.; Sanchez-Madrid, F.; Steinman, L.; Karin, N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature, 1992, 356(6364), 63-6.
145. Stüve, O.; Marra, C.M.; Bar-Or, A.; Niino, M.; Cravens, P.D.; Cepok, S.; Frohman, E.M.; Phillips, J.T.; Arendt, G.; Jerome, K. R.; Cook, L.; Grand'Maison, F.; Hemmer, B.; Monson, N.L.; Racke, M.K. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol., 2006, 63(10), 1383-1387.
146. Lobb, R.R.; Hemler, M.E. The pathophysiologic role of alpha 4 integrins in vivo. J. Clin. Invest., 1994, 94(5), 1722-1728.
147. Bayless, K.J.; Meininger, G.A.; Scholtz, J.M.; Davis, G.E. Osteopontin is a ligand for the alpha4beta1 integrin. J. Cell Sci., 1998, 111(Pt 9), 1165-1174.
148. Polman, C.H.; O'Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M.A.; Sandrock, A.W.; Investigators, A. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354(9), 899-910.
149. Rudick, R.A.; Stuart, W.H.; Calabresi, P.A.; Confavreux, C.; Galetta, S.L.; Radue, E.W.; Lublin, F.D.; Weinstock-Guttman, B.; Wynn, D.R.; Lynn, F.; Panzara, M.A.; Sandrock, A.W.; Investigators, S. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354(9), 911-923.
150. Major, E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med., 2010, 61, 35-47.
151. Major, E.O.; Douek, D.C. Risk factors for rare diseases can be risky to define: PML and natalizumab. Neurology, 2013.
152. Calabresi, P.A.; Giovannoni, G.; Confavreux, C.; Galetta, S.L.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; O'Connor, P.W.; Phillips, J.T.; Polman, C.H.; Radue, E.W.; Rudick, R.A.; Stuart, W.H.; Lublin, F.D.; Wajgt, A.; Weinstock-Guttman, B.; Wynn, D.R.; Lynn, F.; Panzara, M.A.; Investigators, A.A.S. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology, 2007, 69(14), 1391-1403.
153. Vennegoor, A.; Rispens, T.; Strijbis, E.M.; Seewann, A.; Uitdehaag, B.M.; Balk, L.J.; Barkhof, F.; Polman, C.H.; Wolbink, G.; Killestein, J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult. Scler., 2013, 19(5), 593-600.
154. Miller, D.H.; Weber, T.; Grove, R.; Wardell, C.; Horrigan, J.; Graff, O.; Atkinson, G.; Dua, P.; Yousry, T.; Macmanus, D.; Montalban, X. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2012, 11(2), 131-9.
155. Matloubian, M.; Lo, C.G.; Cinamon, G.; Lesneski, M.J.; Xu, Y.; Brinkmann, V.; Allende, M.L.; Proia, R.L.; Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004, 427(6972), 355-360.
156. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov., 2010, 9(11), 883-897.
157. Jackson, S.J.; Giovannoni, G.; Baker, D. Fingolimod modulates microglial activation to augment markers of remyelination. J. Neuroinflammation, 2011, 8, 76.
158. Miron, V.E.; Schubart, A.; Antel, J.P. Central nervous systemdirected effects of FTY720 (fingolimod). J. Neurol. Sci., 2008, 274 (1-2), 13-17.
159. Kappos, L.; Radue, E.W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; Burtin, P.; Group, F.S. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med., 2010, 362(5), 387-401.
160. Cohen, J.A.; Barkhof, F.; Comi, G.; Hartung, H.P.; Khatri, B.O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; Tiel-Wilck, K.; de Vera, A.; Jin, J.; Stites, T.; Wu, S.; Aradhye, S.; Kappos, L.; Group, T.S. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med., 2010, 362(5), 402-215.
161. Schwarz, A.; Korporal, M.; Hosch, W.; Max, R.; Wildemann, B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology, 2010, 74(24), 2022-2024.
162. Leypoldt, F.; Münchau, A.; Moeller, F.; Bester, M.; Gerloff, C.; Heesen, C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology, 2009, 72(11), 1022-1024.
163. Castrop, F.; Kowarik, M.C.; Albrecht, H.; Krause, M.; Haslinger, B.; Zimmer, C.; Berthele, A.; Hemmer, B. Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence? Neurology, 2012, 78(12), 928-930.
164. Visser, F.; Wattjes, M.P.; Pouwels, P.J.; Linssen, W.H.; van Oosten, B.W. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology, 2012, 79(19), 2000-2003.
165. Selmaj, K.; Li, D.K.; Hartung, H.P.; Hemmer, B.; Kappos, L.; Freedman, M.S.; Stüve, O.; Rieckmann, P.; Montalban, X.; Ziemssen, T.; Auberson, L.Z.; Pohlmann, H.; Mercier, F.; Dahlke, F.; Wallström, E. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol,m 2013, 12(8), 756-767.
166. Komiya, T.; Sato, K.; Shioya, H.; Inagaki, Y.; Hagiya, H.; Kozaki, R.; Imai, M.; Takada, Y.; Maeda, T.; Kurata, H.; Kurono, M.; Suzuki, R.; Otsuki, K.; Habashita, H.; Nakade, S. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin. Exp. Immunol., 2013, 171(1), 54-62.
167. Olsson, T.; Boster, A.; Fernández, O.; Freedman, M.S.; Pozzilli, C.; Bach, D.; Berkani, O.; Mueller, M.S.; Sidorenko, T.; Radue, E.W.; Melanson, M. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J. Neurol. Neurosurg. Psychiat., 2014.
168. Wilms, H.; Sievers, J.; Rickert, U.; Rostami-Yazdi, M.; Mrowietz, U.; Lucius, R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation, 2010, 7, 30.
169. Ghoreschi, K.; Brück, J.; Kellerer, C.; Deng, C.; Peng, H.; Rothfuss, O.; Hussain, R.Z.; Gocke, A.R.; Respa, A.; Glocova, I.; Valtcheva, N.; Alexander, E.; Feil, S.; Feil, R.; Schulze-Osthoff, K.; Rupec, R.A.; Lovett-Racke, A.E.; Dringen, R.; Racke, M.K.; Röcken, M. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med., 2011, 208(11), 2291-2303.
170. Linker, R.A.; Lee, D.H.; Ryan, S.; van Dam, A.M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, A.; Chollate, S.; Ellrichmann, G.; Brück, W.; Dawson, K.; Goelz, S.; Wiese, S.; Scannevin, R.H.; Lukashev, M.; Gold, R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain, 2011, 134(Pt 3), 678-692.
171. Fox, R.J.; Miller, D.H.; Phillips, J.T.; Hutchinson, M.; Havrdova, E.; Kita, M.; Yang, M.; Raghupathi, K.; Novas, M.; Sweetser, M.T.; Viglietta, V.; Dawson, K.T.; Investigators, C.S. Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med., 2012, 367(12), 1087-1097.
172. Gold, R.; Kappos, L.; Arnold, D.L.; Bar-Or, A.; Giovannoni, G.; Selmaj, K.; Tornatore, C.; Sweetser, M.T.; Yang, M.; Sheikh, S.I.; Dawson, K.T.; Investigators, D.S. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med., 2012, 367(12), 1098-1107.
173. Ermis, U.; Weis, J.; Schulz, J.B. PML in a patient treated with fumaric acid. N. Engl. J. Med., 2013, 368(17), 1657-1658.
174. van Oosten, B.W.; Killestein, J.; Barkhof, F.; Polman, C.H.; Wattjes, M.P. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N. Engl. J. Med., 2013, 368(17), 1658-1659.
175. Williamson, R.A.; Yea, C.M.; Robson, P.A.; Curnock, A.P.; Gadher, S.; Hambleton, A.B.; Woodward, K.; Bruneau, J.M.; Hambleton, P.; Moss, D.; Thomson, T.A.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautés, C.; Westwood, R.; Hercend, T.; Kuo, E.A.; Ruuth, E. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem., 1995, 270(38), 22467-2272.
176. Claussen, M.C.; Korn, T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin. Immunol., 2012, 142(1), 49-56.
177. O'Connor, P.; Wolinsky, J.S.; Confavreux, C.; Comi, G.; Kappos, L.; Olsson, T.P.; Benzerdjeb, H.; Truffinet, P.; Wang, L.; Miller, A.; Freedman, M.S.; Group, T.T. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med., 2011, 365(14), 1293-1303.
178. Confavreux, C.; O'Connor, P.; Comi, G.; Freedman, M.S.; Miller, A.E.; Olsson, T.P.; Wolinsky, J.S.; Bagulho, T.; Delhay, J.L.; Dukovic, D.; Truffinet, P.; Kappos, L.; Group, T.T. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol., 2014, 13(3), 247-256.
179. Miller, A.; Wolinsky, J.; Kappos, L.; Comi, G.; Freedman, M.S.; Olsson, T.; Rugina, A.; Bauer, D.J.; Delhay, J.; Wamil, B.; Truffinet, P.; O'Connor, P. TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated Syndrome. In Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 2013.
180. Vermersch, P.; Czlonkowska, A.; Grimaldi, L.M.; Confavreux, C.; Comi, G.; Kappos, L.; Olsson, T.P.; Benamor, M.; Bauer, D.; Truffinet, P.; Church, M.; Miller, A.E.; Wolinsky, J.S.; Freedman, M.S.; O'Connor, P.; Group, T.T. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult. Scler., 2014, 20(6), 705-716.
181. Jones, J.L.; Coles, A.J. Campath-1H treatment of multiple sclerosis. Neurodegener. Dis., 2008, 5(1), 27-31.
182. Gilleece, M.H.; Dexter, T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 1993, 82(3), 807-812.
183. Coles, A.J.; Cox, A.; Le Page, E.; Jones, J.; Trip, S.A.; Deans, J.; Seaman, S.; Miller, D.H.; Hale, G.; Waldmann, H.; Compston, D.A. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol., 2006, 253(1), 98-108.
184. Coles, A.J.; Compston, D.A.; Selmaj, K.W.; Lake, S.L.; Moran, S.; Margolin, D.H.; Norris, K.; Tandon, P.K.; Investigators, C.T. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med., 2008, 359(17), 1786-1801.
185. Bourdette, D.; Yadav, V. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Curr. Neurol. Neurosci. Rep., 2009, 9(5), 341-342.
186. Cohen, J.A.; Coles, A.J.; Arnold, D.L.; Confavreux, C.; Fox, E.J.; Hartung, H.P.; Havrdova, E.; Selmaj, K.W.; Weiner, H.L.; Fisher, E.; Brinar, V.V.; Giovannoni, G.; Stojanovic, M.; Ertik, B.I.; Lake, S.L.; Margolin, D.H.; Panzara, M.A.; Compston, D.A.; investigators, C.-M.I. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, 2012, 380(9856), 1819-1828.
187. Coles, A.J.; Twyman, C.L.; Arnold, D.L.; Cohen, J.A.; Confavreux, C.; Fox, E.J.; Hartung, H.P.; Havrdova, E.; Selmaj, K. W.; Weiner, H.L.; Miller, T.; Fisher, E.; Sandbrink, R.; Lake, S.L.; Margolin, D.H.; Oyuela, P.; Panzara, M.A.; Compston, D.A.; investigators, C.-M.I. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet, 2012, 380(9856), 1829-1839.
188. Cary, T.; Pedro, O.; Jeffrey, P.; David, H.M.; Dayan, C. Thyroid autoimmune adverse events in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: Four-year Follow-up of the CARE-MS Studies. In American Academy of Neurology, Annual Meeting, Philadelphia, United States, 2014.
189. Adam, C.; Roberto, S.; Jeffrey, P.; Pedro, O.; David H.M.; Bass, A. Successful detection and management of immune thrombocytopenia in alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis. In American Academy of Neurology, Annual Meeting, Philadelphia, United States, 2014.
190. Reff, M.E.; Carner, K.; Chambers, K.S.; Chinn, P.C.; Leonard, J.E.; Raab, R.; Newman, R.A.; Hanna, N.; Anderson, D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994, 83(2), 435-445.
191. Hauser, S.L.; Waubant, E.; Arnold, D.L.; Vollmer, T.; Antel, J.; Fox, R.J.; Bar-Or, A.; Panzara, M.; Sarkar, N.; Agarwal, S.; Langer-Gould, A.; Smith, C.H.; Group, H.T. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med., 2008, 358(7), 676-688.
192. Naismith, R.T.; Piccio, L.; Lyons, J.A.; Lauber, J.; Tutlam, N.T.; Parks, B.J.; Trinkaus, K.; Song, S.K.; Cross, A.H. Rituximab addon therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology, 2010, 74(23), 1860-1867.
193. Hawker, K.; O'Connor, P.; Freedman, M.S.; Calabresi, P.A.; Antel, J.; Simon, J.; Hauser, S.; Waubant, E.; Vollmer, T.; Panitch, H.; Zhang, J.; Chin, P.; Smith, C.H.; group, O.T. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol., 2009, 66(4), 460-471.
194. Carson, K.R.; Evens, A.M.; Richey, E.A.; Habermann, T.M.; Focosi, D.; Seymour, J.F.; Laubach, J.; Bawn, S.D.; Gordon, L.I.; Winter, J.N.; Furman, R.R.; Vose, J. M.; Zelenetz, A.D.; Mamtani, R.; Raisch, D.W.; Dorshimer, G.W.; Rosen, S.T.; Muro, K.; Gottardi-Littell, N.R.; Talley, R.L.; Sartor, O.; Green, D.; Major, E.O.; Bennett, C.L. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 2009, 113(20), 4834-4840.
195. Genovese, M.C.; Kaine, J.L.; Lowenstein, M.B.; Del Giudice, J.; Baldassare, A.; Schechtman, J.; Fudman, E.; Kohen, M.; Gujrathi, S.; Trapp, R.G.; Sweiss, N.J.; Spaniolo, G.; Dummer, W.; Group, A.S. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum., 2008, 58(9), 2652-2661.
196. Kappos, L.; Li, D.; Calabresi, P.A.; O'Connor, P.; Bar-Or, A.; Barkhof, F.; Yin, M.; Leppert, D.; Glanzman, R.; Tinbergen, J.; Hauser, S.L. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet, 2011, 378(9805), 1779-1787.
197. Sorensen, P.S.; Lisby, S.; Grove, R.; Derosier, F.; Shackelford, S.; Havrdova, E.; Drulovic, J.; Filippi, M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study. Neurology, 2014, 82(7), 573-581.
198. Martin, R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin. Immunol., 2012, 142(1), 9-14.
199. Bielekova, B.; Catalfamo, M.; Reichert-Scrivner, S.; Packer, A.; Cerna, M.; Waldmann, T.A.; McFarland, H.; Henkart, P.A.; Martin, R., Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA, 2006, 103(15), 5941-5946.
200. Gold, R.; Giovannoni, G.; Selmaj, K.; Havrdova, E.; Montalban, X.; Radue, E.W.; Stefoski, D.; Robinson, R.; Riester, K.; Rana, J.; Elkins, J.; O'Neill, G. Daclizumab high-yield process in relapsingremitting multiple sclerosis (SELECT): A randomised, doubleblind, placebo-controlled trial. Lancet, 2013, 381(9884), 2167-2175.
201. Bielekova, B.; Richert, N.; Herman, M.L.; Ohayon, J.; Waldmann, T.A.; McFarland, H.; Martin, R.; Blevins, G. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology, 2011, 77 (21), 1877-1886.
202. Hao, J.; Campagnolo, D.; Liu, R.; Piao, W.; Shi, S.; Hu, B.; Xiang, R.; Zhou, Q.; Vollmer, T.; Van Kaer, L.; La Cava, A.; Shi, F.D. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol., 2011, 69(4), 721-734.
203. Wynn, D.; Kaufman, M.; Montalban, X.; Vollmer, T.; Simon, J.; Elkins, J.; O'Neill, G.; Neyer, L.; Sheridan, J.; Wang, C.; Fong, A.; Rose, J.W. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta. Lancet Neurol., 2010, 9(4), 381-390.
204. Wuest, S.C.; Edwan, J.H.; Martin, J.F.; Han, S.; Perry, J.S.; Cartagena, C.M.; Matsuura, E.; Maric, D.; Waldmann, T.A.; Bielekova, B. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med., 2011, 17(5), 604-609.
205. Perry, J.S.; Han, S.; Xu, Q.; Herman, M.L.; Kennedy, L.B.; Csako, G.; Bielekova, B. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med., 2012, 4(145), 145ra106.
206. Rose, J.W.; Watt, H.E.; White, A.T.; Carlson, N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol., 2004, 56(6), 864-867.
207. Rose, J.W.; Burns, J.B.; Bjorklund, J.; Klein, J.; Watt, H.E.; Carlson, N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology, 2007, 69 (8), 785-789.
208. Oh, J.; Saidha, S.; Cortese, I.; Ohayon, J.; Bielekova, B.; Calabresi, P.A.; Newsome, S.D. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology, 2014, 82 (11), 984-988.
209. Giovannoni, G.; Gold, R.; Selmaj, K.; Havrdova, E.; Montalban, X.; Radue, E.-W.; Stefoski, D.; McNeill, M.; Rana, J.; Elkins, J.; O'Neill, G. Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis. In Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Lyon, France, 2012.
210. Giovannoni, G.; Gold, R.; Selmaj, K.; Havrdova, E.; Montalban, X.; Radue, E.W.; Stefoski, D.; McNeill, M.; Amaravadi, L.; Sweetser, M.; Elkins, J.; O'Neill, G.; Investigators, S.S. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial. Lancet Neurol., 2014, 13(5), 472-481.
211. Ohayon, J.; Oh, U.; Richert, N.; Martin, J.; Vortmeyer, A.; McFarland, H.; Bielekova, B. CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology, 2013, 80(5), 453-457.
212. Marriott, J.J.; Miyasaki, J.M.; Gronseth, G.; O'Connor, P.W.; Neurology, T. a. T. A. S. o. t. A. A. o. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2010, 74(18), 1463-1470.
213. Hartung, H.P.; Gonsette, R.; König, N.; Kwiecinski, H.; Guseo, A.; Morrissey, S.P.; Krapf, H.; Zwingers, T.; (MIMS), M. i. M. S. S. G., Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial. Lancet, 2002, 360(9350), 2018-2025.
214. Krapf, H.; Morrissey, S.P.; Zenker, O.; Zwingers, T.; Gonsette, R.; Hartung, H.P.; Group, M.S. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology, 2005, 65(5), 690-695.
215. Noseworthy, J.H.; Wolinsky, J.S.; Lublin, F.D.; Whitaker, J.N.; Linde, A.; Gjorstrup, P.; Sullivan, H.C. Linomide in relapsing and secondary progressive MS: part I: Trial design and clinical results. North American Linomide Investigators. Neurology, 2000, 54(9), 1726-1733.
216. Wolinsky, J.S.; Narayana, P.A.; Noseworthy, J.H.; Lublin, F.D.; Whitaker, J.N.; Linde, A.; Gjorstrup, P.; Sullivan, H.C. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology, 2000, 54(9), 1734-1741.
217. Tan, I.L.; Lycklama a Nijeholt, G.J.; Polman, C.H.; Ader, H.J.; Barkhof, F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult. Scler., 2000, 6(2), 99-104.
218. Bruck, W.; Wegner, C. Insight into the mechanism of laquinimod action. J. Neurol. Sci., 2011, 306(1-2), 173-179.
219. Wegner, C.; Stadelmann, C.; Pfortner, R.; Raymond, E.; Feigelson, S.; Alon, R.; Timan, B.; Hayardeny, L.; Bruck, W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2010, 227(1-2), 133-143.
220. Yang, J.S.; Xu, L.Y.; Xiao, B.G.; Hedlund, G.; Link, H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol., 2004, 156(1-2), 3-9.
221. Gurevich, M.; Gritzman, T.; Orbach, R.; Tuller, T.; Feldman, A.; Achiron, A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In vitro high-throughput gene expression study. J. Neuroimmunol., 2010, 221(1-2), 87-94.
222. Schulze-Topphoff, U.; Shetty, A.; Varrin-Doyer, M.; Molnarfi, N.; Sagan, S.A.; Sobel, R.A.; Nelson, P.A.; Zamvil, S.S. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One, 2012, 7(3), e33797.
223. Brunmark, C.; Runstrom, A.; Ohlsson, L.; Sparre, B.; Brodin, T.; Astrom, M.; Hedlund, G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2002, 130(1-2), 163-172.
224. Aharoni, R.; Saada, R.; Eilam, R.; Hayardeny, L.; Sela, M.; Arnon, R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2012, 251(1-2), 14-24.
225. Thone, J.; Ellrichmann, G.; Seubert, S.; Peruga, I.; Lee, D.H.; Conrad, R.; Hayardeny, L.; Comi, G.; Wiese, S.; Linker, R.A.; Gold, R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol., 2012, 180(1), 267-274.
226. Comi, G.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A.; Rocca, M.A.; Filippi, M. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med., 2012, 366(11), 1000-1009.
227. Vollmer, T.; Soelberg Sorensen, P.; Arnold, D.L. A placebocontrolled and active comparator phase III trial (BRAVO) in relapsing-remitting multiple sclerosis. In 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 2011.
228. The Efficacy and Safety and Tolerability of Laquinimod in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (CONCERTO) NCT01707992. http://clinicaltrials.gov/ct2/show/NCT01707992?term=Laquinimod&rank=6 (accessed 20.08.2013).
229. Beutler, E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992, 340(8825), 952-956.
230. Singh, V.; Prajeeth, C.K.; Gudi, V.; Benardais, K.; Voss, E.V.; Stangel, M. 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin. Exp. Immunol., 2013, 173(2), 288-297.
231. Mitosek-Szewczyk, K.; Tabarkiewicz, J.; Wilczynska, B.; Lobejko, K.; Berbecki, J.; Nastaj, M.; Dworzanska, E.; Kolodziejczyk, B.; Stelmasiak, Z.; Rolinski, J. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. J. Neurol. Sci., 2013, 332(1-2), 35-40.
232. Kopadze, T.; Dobert, M.; Leussink, V.I.; Dehmel, T.; Kieseier, B. C. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur. J. Neurol., 2009, 16(3), 409-412.
233. Hartung, H.P.; Aktas, O.; Kieseier, B.; Giancarlo, C.G.C. Development of oral cladribine for the treatment of multiple sclerosis. J. Neurol., 2010, 257(2), 163-170.
234. Kay, A.C.; Saven, A.; Carrera, C.J.; Carson, D.A.; Thurston, D.; Beutler, E.; Piro, L.D. 2-Chlorodeoxyadenosine treatment of lowgrade lymphomas. J. Clin. Oncol., 1992, 10(3), 371-377.
235. Piro, L.D.; Carrera, C.J.; Carson, D.A.; Beutler, E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med., 1990, 322(16), 1117-1121.
236. Romine, J.S.; Sipe, J.C.; Koziol, J.A.; Zyroff, J.; Beutler, E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians, 1999, 111(1), 35-44.
237. Beutler, E.; Sipe, J. C.; Romine, J.S.; Koziol, J.A.; McMillan, R.; Zyroff, J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. USA, 1996, 93(4), 1716-1720.
238. Rice, G.P.; Filippi, M.; Comi, G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology, 2000, 54(5), 1145-1155.
239. Giovannoni, G.; Comi, G.; Cook, S.; Rammohan, K.; Rieckmann, P.; Soelberg Sorensen, P.; Vermersch, P.; Chang, P.; Hamlett, A.; Musch, B.; Greenberg, S.J. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med., 2010, 362(5), 416-426.
240. Comi, G.; Cook, S.D.; Giovannoni, G.; Rammohan, K.; Rieckmann, P.; Sorensen, P.S.; Vermersch, P.; Hamlett, A.C.; Viglietta, V.; Greenberg, S.J. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J. Neurol., 2013, 260(4), 1136-1146.
241. Giovannoni, G.; Comi, G.; Cook, S.; Rammohan, K.; Rieckmann, P.; Soelberg-Sorensen, P.; Vermersch, P.; Hamlett, A.; Scaramozza, M.; Lachenal, N. Safety and efficacy of oral cladribine in patients with relapsing-remitting multiple sclerosis: results from the 96 week phase IIIb extension trial to the CLARITY Study (P07.119). Neurology, 2013, 80 (Meeting Abstracts 1), P07.119.
242. Montalban, X.; Cohen, B.; Leist, T.; Moses, H.; Hamlett, A.; Scaramozza, M.; Lachenal, N. Oral Cladribine as Add on to IFN {beta} Therapy in Patients with Active Multiple Sclerosis: Results from the Phase II ONWARD Study (P07.099). Neurology, 2013, 80 (Meeting Abstracts 1), P07.099.
243. Leist, T.; Comi, G.; Cree, B.; Coyle, P.; Freedman, M.; Hartung, H.; Vermersch, P.; Orejudos, A.; Lachenal, N.; Scaramozza, M. Oral cladribine delays time to conversion to clinically definite MS in patients with a first demyelinating event: Top line results from the phase III ORACLE MS Study (P07.114). Neurology, 2013, 80 (Meeting Abstracts 1), P07.114.
244. Cook, S.; Vermersch, P.; Comi, G.; Giovannoni, G.; Rammohan, K.; Rieckmann, P.; Sorensen, P.S.; Hamlett, A.; Miret, M.; Weiner, J.; Viglietta, V.; Musch, B.; Greenberg, S.J. Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult. Scler., 2011, 17(5), 578-593.
245. Comi, G.; Hartung, H.P.; Kurukulasuriya, N.C.; Greenberg, S.J.; Scaramozza, M. Cladribine tablets for the treatment of relapsingremitting multiple sclerosis. Expert Opin. Pharmacother., 2013, 14(1), 123-136.